A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the MTD and dose-limiting toxicities of recombinant interleukin-2 (aldesleukin;
Proleukin) administered subcutaneously in HIV-seropositive patients. To identify a tolerable
subcutaneous regimen that will replicate the immunologic improvement demonstrated in the
outpatient polyethylene glycolated IL-2 and high-dose continuous infusion IL-2 studies. To
evaluate the incidence and level of anti-IL-2 antibody formation to subcutaneously
administered Proleukin in this patient population.